Teva- Pharmaceutical Industries Ltd. TEVA

NYS: TEVA | ISIN: US8816242098   19/12/2025
30,35 USD (+0,10%)
(+0,10%)   19/12/2025
Grafiek Teva- Pharmaceutical Industries Ltd. Grafiek Teva- Pharmaceutical Industries Ltd.
woensdag 28 januari 2026, 13:00
Kwartaalcijfers (4de kwartaal)

Teva- Pharmaceutical Industries Ltd. in het nieuws

19 december 2025 · Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® · Persbericht

12 december 2025 · Teva Releases Q4 2025 Aide Memoire · Persbericht

12 december 2025 · Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 · Persbericht

9 december 2025 · Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults · Persbericht

26 november 2025 · Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva® · Persbericht

25 november 2025 · Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® · Persbericht

21 november 2025 · Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December · Persbericht

19 november 2025 · Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges · Persbericht

8 november 2025 · AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living · Persbericht

5 november 2025 · Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS · Persbericht

Profiel Teva- Pharmaceutical Industries Ltd.

Fabricage van farmaceutische preparaten
Farmaceutische Producten: Generisch
Gezondheidstechnologie
Productie

Mijn selecties